CD73: a potential biomarker for anti-PD-1 therapy

Paul A Beavis, Clare Y Slaney, Nicole Milenkovski, Melissa A Henderson, Sherene Loi, John Stagg, Michael H Kershaw, Phillip K Darcy

Research output: Contribution to journalComment / DebateResearchpeer-review

19 Citations (Scopus)

Abstract

In our recent study, we show that tumoral CD73 expression limits the efficacy of anti-PD-1 therapy, and this is rescued by concomitant A2A blockade. Since CD73 is known to be overexpressed in several human cancers and A2A antagonists have undergone clinical trials for Parkinson s Disease, this combination warrants further investigation. ? 2015, Taylor Francis Group, LLC
Original languageEnglish
Pages (from-to)1 - 3
Number of pages3
JournalOncoImmunology
Volume4
Issue number11
DOIs
Publication statusPublished - 2015

Cite this